A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.
CDX2
disease progression
progesterone receptor
progression
special AT-rich sequence-binding protein 2
survival
β-catenin
Journal
The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
13
12
2018
revised:
08
03
2019
accepted:
25
03
2019
pubmed:
30
3
2019
medline:
30
7
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
The aim of this study was to describe the expression of special AT-rich sequence-binding protein 2 (SATB2) in ovarian endometrioid carcinoma (EC). SATB2 is a nuclear matrix-associated transcription factor that is associated with abnormal expression in certain cancers but has not been reported for ovarian carcinoma. SATB2 mRNA and protein expression was first assessed in a pilot cohort of 26 samples by Affymetrix microarray and by routine immunohistochemistry on a small tissue microarray. A large multicenter validation cohort representing the well-characterized cases of 235 ovarian EC from the Canadian Ovarian Experimental Unified Resource (COEUR) was then used to validate this result and to assess the prognostic impact of SATB2 expression. SATB2 staining was scored as negative, weak, moderate, and strong intensity, and by percentage of stained cells. No SATB2 expression was observed in clear cell carcinomas but 10% (n = 3) of the ECs in the pilot cohort showed SATB2 expression. In the validation cohort, strong expression was observed in 11% of ECs, while weak or moderate expression levels were detected in 12% of cases. Evaluation of SATB2 expression with clinicopathological parameters revealed an association with patient age and Federation International of Gynecology and Obstetrics grade but not with disease stage or postoperative residual disease. Any expression of SATB2, independent of intensity, was also associated with longer survival and improved progression-free survival with hazard ratio (HR) = 0.14 (95% CI 0.03-0.56) and HR = 0.16 (95% CI 0.02-1.24) respectively. A greater beneficial effect was observed in patients with stage III/IV disease compared to patients with stage I/II disease. Furthermore, direct comparison of SATB2 with other reported prognostic biomarkers such as progesterone receptor, CDX2 and β-catenin within this cohort showed that SATB2 had the strongest association with survival. Given the current lack of accurate prognostic factors for these patients, SATB2 has promising clinical utility and warrants further study.
Identifiants
pubmed: 30924313
doi: 10.1002/cjp2.131
pmc: PMC6648975
doi:
Substances chimiques
Biomarkers, Tumor
0
Matrix Attachment Region Binding Proteins
0
SATB2 protein, human
0
Transcription Factors
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-188Informations de copyright
© 2019 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.
Références
Br J Cancer. 2001 Jan;84(2):209-17
pubmed: 11161379
Cancer Res. 2001 Nov 15;61(22):8247-55
pubmed: 11719457
Genes Dev. 2003 Dec 15;17(24):3048-61
pubmed: 14701874
Hum Pathol. 2004 Nov;35(11):1360-8
pubmed: 15668893
Eur J Neurosci. 2005 Feb;21(3):658-68
pubmed: 15733084
Int J Cancer. 2006 Apr 1;118(7):1750-8
pubmed: 16217764
Br J Cancer. 2006 Feb 13;94(3):436-45
pubmed: 16421595
Br J Cancer. 2008 Jan 29;98(2):282-8
pubmed: 18219286
Histopathology. 2008 Aug;53(2):156-65
pubmed: 18752499
Virchows Arch. 2008 Nov;453(5):521-7
pubmed: 18843504
PLoS Med. 2008 Dec 2;5(12):e232
pubmed: 19053170
Mod Pathol. 2009 Feb;22(2):167-74
pubmed: 19180120
Cancer Cell Int. 2009 Jul 30;9:18
pubmed: 19642980
Int J Gynecol Pathol. 2010 May;29(3):203-11
pubmed: 20407318
Am J Surg Pathol. 2011 Jul;35(7):937-48
pubmed: 21677534
Br J Cancer. 2012 Feb 28;106(5):931-8
pubmed: 22333599
J Biomed Res. 2010 Jul;24(4):257-63
pubmed: 23554638
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Biopreserv Biobank. 2013 Apr;11(2):83-93
pubmed: 24845429
Int J Clin Exp Pathol. 2015 Apr 01;8(4):3710-8
pubmed: 26097552
Int J Gynecol Cancer. 2015 Sep;25(7):1187-93
pubmed: 26166557
Int J Gynecol Pathol. 2016 May;35(3):191-208
pubmed: 26535987
Am J Surg Pathol. 2016 Mar;40(3):419-32
pubmed: 26551622
Cancer Cytopathol. 2015 Dec;123(12):706-13
pubmed: 26671737
Oncotarget. 2016 Jan 26;7(4):4993-5006
pubmed: 26701851
Int J Gynecol Pathol. 2016 Sep;35(5):430-41
pubmed: 26974996
Stem Cell Res. 2017 Mar;19:139-147
pubmed: 28167342
Int J Mol Sci. 2017 Feb 27;18(3):
pubmed: 28264438
Nat Genet. 2017 Jun;49(6):856-865
pubmed: 28436987
Hum Pathol. 2017 Sep;67:152-159
pubmed: 28711650
Int J Surg Pathol. 2018 Jun;26(4):306-317
pubmed: 29338553
Anticancer Res. 2018 Feb;38(2):839-846
pubmed: 29374710
BMC Cancer. 2018 Mar 27;18(1):347
pubmed: 29587661
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
J Pathol Clin Res. 2018 Oct;4(4):250-261
pubmed: 30062862
Int J Gynecol Pathol. 2018 Aug 06;:null
pubmed: 30085940
J Carcinog. 2018 Apr 05;17:2
pubmed: 30123095
Am J Surg Pathol. 2019 Feb;43(2):235-243
pubmed: 30256257
Histopathology. 2019 Feb;74(3):452-462
pubmed: 30326146
Oncogene. 2019 Mar;38(12):1989-2004
pubmed: 30413763
Br J Cancer. 1995 Aug;72(2):376-82
pubmed: 7640221
Int J Cancer. 1995 Dec 20;64(6):361-6
pubmed: 8550235
Histopathology. 1998 Jan;32(1):69-80
pubmed: 9522220
Cancer Res. 1998 May 15;58(10):2095-7
pubmed: 9605750